Article Information
History
- July 20, 2022.
Article Versions
- You are currently viewing Version 1 of this article (July 20, 2022 - 00:22).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Anja Hess1,2,
- Stefan D. Gentile1,3,
- Amel Ben Saad1,3,
- Raza-Ur Rahman1,3,
- Tim Habboub1 and
- Alan C. Mullen1,3,4,5,6,*
- 1Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA
- 2Max Planck Institute for Molecular Genetics, Department of Genome Regulation, Berlin, Germany
- 3Harvard Medical School, Boston, MA, USA
- 4Harvard Stem Cell Institute, Cambridge, MA, USA
- 5Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 6Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, MA, USA
- ↵* Corresponding author. GRJ7, 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114, USA. (617) 726-6342. Email: acmullen{at}mgh.harvard.edu
Posted July 20, 2022.
Human liver organoids model progressive inflammatory and fibrotic injury in non-alcoholic fatty liver disease
